Raising the Science Standard for New Drug Development (Paperback)
3 Angebote vergleichen
Bester Preis: Fr. 39.02 (€ 39.90)¹ (vom 01.04.2015)1
Symbolbild
Raising the Science Standard for New Drug Development (Paperback) (2015)
DE PB NW RPISBN: 9783659395185 bzw. 3659395188, in Deutsch, Omniscriptum Gmbh Co. Kg, Taschenbuch, neu, Nachdruck.
Lieferung aus: Deutschland, Versandkostenfrei.
Von Händler/Antiquariat, The Book Depository EURO [60485773], Slough, United Kingdom.
Language: English Brand New Book ***** Print on Demand *****.New drug development has sunk into a state of doldrums in spite of explosive advancement of basic research, especially in human genomics, and enormous investment from both government and industry. 2007 was the worst rate of new drug approvals in a quarter of a century in the U.S. experience. This book proposes raising the science standard for new drug approvals to end the race to the bottom the biopharmaceutical sectors are engaged in, and to enhance the role of the U.S. government in new drug development along the lines of the Manhattan Project and the Human Genome Project.
Von Händler/Antiquariat, The Book Depository EURO [60485773], Slough, United Kingdom.
Language: English Brand New Book ***** Print on Demand *****.New drug development has sunk into a state of doldrums in spite of explosive advancement of basic research, especially in human genomics, and enormous investment from both government and industry. 2007 was the worst rate of new drug approvals in a quarter of a century in the U.S. experience. This book proposes raising the science standard for new drug approvals to end the race to the bottom the biopharmaceutical sectors are engaged in, and to enhance the role of the U.S. government in new drug development along the lines of the Manhattan Project and the Human Genome Project.
2
Symbolbild
Raising the Science Standard for New Drug Development (2007)
DE PB NW RPISBN: 9783659395185 bzw. 3659395188, in Deutsch, LAP Lambert Academic Publishing, Taschenbuch, neu, Nachdruck.
Von Händler/Antiquariat, AHA-BUCH GmbH [51283250], Einbeck, Germany.
This item is printed on demand - Print on Demand Titel. Neuware - New drug development has sunk into a state of doldrums in spite of explosive advancement of basic research, especially in human genomics, and enormous investment from both government and industry. 2007 was the worst rate of new drug approvals in a quarter of a century in the U.S. experience. This book proposes raising the science standard for new drug approvals to end the 'race to the bottom' the biopharmaceutical sectors are engaged in, and to enhance the role of the U.S. government in new drug development along the lines of the Manhattan Project and the Human Genome Project. 124 pp. Englisch.
This item is printed on demand - Print on Demand Titel. Neuware - New drug development has sunk into a state of doldrums in spite of explosive advancement of basic research, especially in human genomics, and enormous investment from both government and industry. 2007 was the worst rate of new drug approvals in a quarter of a century in the U.S. experience. This book proposes raising the science standard for new drug approvals to end the 'race to the bottom' the biopharmaceutical sectors are engaged in, and to enhance the role of the U.S. government in new drug development along the lines of the Manhattan Project and the Human Genome Project. 124 pp. Englisch.
3
Raising the Science Standard for New Drug Development
DE NWISBN: 9783659395185 bzw. 3659395188, in Deutsch, neu.
Lieferung aus: Deutschland, zzgl. Versandkosten.
New drug development has sunk into a state of doldrums in spite of explosive advancement of basic research, especially in human genomics, and enormous investment from both government and industry. 2007 was the worst rate of new drug approvals in a quarter of a century in the U.S. experience. This book proposes raising the science standard for new drug approvals to end the "race to the bottom" the biopharmaceutical sectors are engaged in, and to enhance the role of the U.S. government in new drug development along the lines of the Manhattan Project and the Human Genome Project.
New drug development has sunk into a state of doldrums in spite of explosive advancement of basic research, especially in human genomics, and enormous investment from both government and industry. 2007 was the worst rate of new drug approvals in a quarter of a century in the U.S. experience. This book proposes raising the science standard for new drug approvals to end the "race to the bottom" the biopharmaceutical sectors are engaged in, and to enhance the role of the U.S. government in new drug development along the lines of the Manhattan Project and the Human Genome Project.
Lade…